Abstract
Reduced intensity conditioning followed by allogeneic SCT (RIC-SCT) has recently emerged as promising new salvage option for children suffering from Langerhans cell histiocytosis (LCH) with risk organ involvement and failure to conventional therapy. We report on the posttransplant course of female toddler with high-risk LCH, who achieved complete remission after RIC-SCT, despite a posttransplant chimerism constellation, in which only the T-cell subset proved to be of donor origin in the long-term. We therefore suggest that allogeneic T-cells have played a crucial role in controlling disease activity in this patient and may exert the major curative effect after RIC-SCT for LCH.References
- Arceci RJ. The histiocytoses: the fall of the Tower of Babel. Eur J Cancer. 1999; 35(5):747-67. Google Scholar
- Gadner H, Heitger A, Grois N, Gatterer-Menz I, Ladisch S. Treatment strategy for disseminated Langerhans cell histiocytosis. DAL HX-83 Study Group. Med Pediatr Oncol. 1994; 23(2):72-80. Google Scholar
- Gadner H, Grois N, Arico M, Broadbent V, Ceci A, Jakobson A. A randomized trial of treatment for multisystem Langerhans’ cell histiocytosis. J Pediatr. 2001; 138(5):728-34. Google Scholar
- Steiner M, Matthes-Martin S, Attarbaschi A, Minkov M, Grois N, Unger E. Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant. 2005; 36(3):215-25. Google Scholar
- Annels NE, Da Costa CE, Prins FA, Willemze A, Hogendoorn PC, Egeler RM. Aberrant chemokine receptor expression and chemokine production by Langerhans cells underlies the pathogenesis of Langerhans cell histiocytosis. J Exp Med. 2003; 197(10):1385-90. Google Scholar
- Laman JD, Leenen PJ, Annels NE, Hogendoorn PC, Egeler RM. Langerhans-cell histiocytosis ‘insight into DC biology’. Trends Immunol. 2003; 24(4):190-6. Google Scholar
- Willman CL. Detection of clonal histiocytes in Langerhans cell histiocytosis: biology and clinical significance. Br J Cancer Suppl. 1994; 23:S29-33. Google Scholar
- Egeler RM, Favara BE, Laman JD, Claassen E. Abundant expression of CD40 and CD40-ligand (CD154) in paediatric Langerhans cell histiocytosis lesions. Eur J Cancer. 2000; 36(16):2105-10. Google Scholar
- Jordan MB, McClain KL, Yan X, Hicks J, Jaffe R. Anti-CD52 antibody, alemtuzumab, binds to Langerhans cells in Langerhans cell histiocytosis. Pediatr Blood Cancer. 2005; 44(3):251-4. Google Scholar